Lavie v. Procter & Gamble Co.

129 Cal. Rptr. 2d 486, 105 Cal. App. 4th 496, 2003 Daily Journal DAR 699, 2003 Cal. Daily Op. Serv. 612, 2003 Cal. App. LEXIS 71
CourtCalifornia Court of Appeal
DecidedJanuary 17, 2003
DocketA093393
StatusPublished
Cited by210 cases

This text of 129 Cal. Rptr. 2d 486 (Lavie v. Procter & Gamble Co.) is published on Counsel Stack Legal Research, covering California Court of Appeal primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Lavie v. Procter & Gamble Co., 129 Cal. Rptr. 2d 486, 105 Cal. App. 4th 496, 2003 Daily Journal DAR 699, 2003 Cal. Daily Op. Serv. 612, 2003 Cal. App. LEXIS 71 (Cal. Ct. App. 2003).

Opinions

Opinion

KLINE, P. J.

Introduction

This appeal arises out of appellant’s challenge to allegedly deceptive television commercials supporting the launch of Aleve, a nonprescription pain relief product developed, manufactured and marketed by respondents. Plaintiff-appellant Zion Lavie appeals from the judgment against him and in favor of defendants-respondents Procter & Gamble Co. (Procter & Gamble), [500]*500Syntex Health Products, Inc. (Syntex), Procter-Syntex Health Products Company (Procter-Syntex), and others,1 following a court trial upon appellant’s action challenging television advertising supporting the launch of ProcterSyntex nonprescription pain reliever Aleve in the mid-1990’s. Among other claims, appellant alleged the television advertising promoting Aleve violated the California unfair competition law (Bus. & Prof. Code, § 17200) (UCL) and this state’s false advertising law (Bus. & Prof. Code, § 17500)2 because the explicit claim of the ads that “Aleve is gentler to the stomach lining than aspirin” was false and/or likely to mislead members of the public and because the advertisements contained an implicit and false message that Aleve was gentle to the stomach and would not cause stomach upset. At the end of a 13-day bench trial, the trial court found in favor of respondents on all counts, including finding that respondents did not engage in unlawful, unfair or fraudulent business practices or unfair, deceptive or misleading advertising within the meaning of section 17200 or 17500. The court found the substantial weight of the evidence supported the conclusion that the phrase “Aleve is gentler to your stomach lining than aspirin” was a true statement and that the challenged ads were not likely to deceive reasonable consumers. The court also found that the ads did not target particularly gullible consumers and that the evidence did not show that a substantial number of consumers were deceived into thinking Aleve would not cause gastrointestinal side effects.

Appellant contends the judgment must be reversed as the court erred: (1) in employing the wrong methodology in determining what messages were conveyed by the commercial, relying upon its own intuition rather than viewing the ads from the vantage point of a reasonable consumer; (2) by disregarding evidence showing the messages were misleading and unsupported by the medical data; and (3) by disregarding evidence that these messages were impressed upon a significant number of consumers and were therefore likely to deceive the public. Appellant also contends that the evidence established defendants’ conscious decision to communicate implied messages they knew would mislead many California consumers, and that such was an unfair business practice under section 17200. Finally, he argues that if the matter is reversed, the trial court on remand has discretion to enter restitution relief.

The Attorney General has filed an amicus curiae brief in this appeal, contending the likelihood of deception under the UCL must be measured by [501]*501the standard of the “least sophisticated consumer” and that the trial court erred in using a “reasonable consumer” standard to determine whether the advertisements were likely to deceive the public.

We shall affirm the judgment.

The lawsuit.3

In June 1994, Aleve was brought to the market as a new addition to over-the-counter pain relief products. Appellant, aged 47, is a computer programmer and manager. He testified that he took Aleve in mid-December 1994 for relief of cold symptoms. Twelve years before, he had been diagnosed with an ulcer and his doctor had told him to avoid aspirin. The ulcer had been inactive. Appellant decided to try Aleve after seeing some newspaper and television ads. He took Aleve over the weekend and on the following Monday was hospitalized overnight with serious gastrointestinal bleeding. His doctor told him not to use Aleve and appellant presented evidence the bleeding was caused by his ingestion of Aleve.

Appellant wrote to Procter & Gamble about his problem, stating he believed the company should be working on revising its warning label. Procter & Gamble responded by offering him his purchase price plus interest and requesting the name of his doctor, so the matter could be looked into. Plaintiff did not accept return of the purchase price. He sued respondents on various claims centering on the allegation that the television advertising for Aleve was false, misleading and/or likely to mislead. He asserted claims both individually and on behalf of the general public for violation of the UCL (§ 17200 et seq.) and the false advertising act (§ 17500). He also asserted claims for common law fraud, negligent misrepresentation, and violation of the Consumers Legal Remedies Act (Civ. Code, § 1750 et seq.). Although he eventually waived any claims for personal injury, appellant sought restitution for himself and the general public with respect to his UCL and false advertising claims in the amount of all sales of Aleve to customers in California (a sum ranging from approximately $104 million to $140 million) and injunctive relief in the form of corrective advertising. Appellant also sought actual and punitive damages under his common law and Consumers Legal Remedies Act claims. Finally, he sought to have any monetary relief awarded under the UCL or the Consumers Legal Remedies Act enhanced up to treble the amount awarded pursuant to Civil Code section 3345.

At the end of a 13-day bench trial, the Honorable Isabella H. Grant found against appellant and in favor of respondents on all claims, including finding [502]*502that defendants did not engage in unlawful, unfair or fraudulent business practices or unfair, deceptive or misleading advertising within the meaning of section 17200 or 17500. Judgment was entered on October 11, 2000, and this timely appeal followed. Appellant challenges the judgment against him on his UCL and false advertising claims only.

I. California laws prohibiting unfair competition (§ 17200 et seq.) and false advertising (§ 17500).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Summer Whiteside v. Kimberly Clark Corp.
108 F.4th 771 (Ninth Circuit, 2024)
Sepanossian v. Nat. Ready Mix Co.
California Court of Appeal, 2023
Zepeda v. Superior Court
California Court of Appeal, 2023
Zimmerman v. L'Oreal USA, Inc.
N.D. California, 2023
Sean McGinity v. the Procter & Gamble Company
69 F.4th 1093 (Ninth Circuit, 2023)
Jason v. Pardini CA1/2
California Court of Appeal, 2023
Ary v. Target Corporation
N.D. California, 2023
Drake v. Bayer Healthcare LLC
S.D. California, 2023
Leventhal v. Streamlabs LLC
N.D. California, 2022
People v. Ramsey CA5
California Court of Appeal, 2022

Cite This Page — Counsel Stack

Bluebook (online)
129 Cal. Rptr. 2d 486, 105 Cal. App. 4th 496, 2003 Daily Journal DAR 699, 2003 Cal. Daily Op. Serv. 612, 2003 Cal. App. LEXIS 71, Counsel Stack Legal Research, https://law.counselstack.com/opinion/lavie-v-procter-gamble-co-calctapp-2003.